Ratings by Raymond James (Dane Leone)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 12/8/2025 | Ocular Therapeutix | OCUL | Maintain | Strong Buy (N/A) |
|
Details | ||
| 8/5/2025 | Ocular Therapeutix | OCUL | Maintain | Strong Buy (N/A) |
|
Details | ||
| 8/4/2025 | Ocular Therapeutix | OCUL | Maintain | Strong Buy (N/A) |
|
Details | ||
| 7/18/2025 | Bristol-Myers Squibb Co. | BMY | Maintain | Market Perform (N/A) |
|
Details | ||
| 6/2/2025 | Bristol-Myers Squibb Co. | BMY | Maintain | Market Perform (N/A) |
|
Details | ||
| 5/5/2025 | Ocular Therapeutix | OCUL | Maintain | Strong Buy (N/A) |
|
Details | ||
| 4/2/2025 | Cytokinetics | CYTK | Maintain | Outperform (N/A) |
|
Details | ||
| 3/3/2025 | Ocular Therapeutix | OCUL | Maintain | Strong Buy (N/A) |
|
Details | ||
| 2/5/2025 | Ocular Therapeutix | OCUL | Maintain | Strong Buy (N/A) |
|
Details | ||
| 2/3/2025 | Blueprint Medicines | BPMC | Maintain | Strong Buy (N/A) |
|
Details | ||
| 10/10/2024 | Regenxbio Inc. | RGNX | New Coverage | Outperform (N/A) |
9.24 (8.43) |
-8.77% | Details | |
| 8/7/2024 | G1 Therapeutics | GTHX | Downgrade | Market Perform (Outperform) |
4.25 (7.15) |
68.24% | Details | |
| 11/16/2023 | Revolution | RVMD | New Coverage | Outperform (N/A) |
20.87 (98.40) |
371.49% | Details | |
| 11/3/2023 | Regeneron Pharma | REGN | Upgrade | Outperform (Market Perform) |
791.27 (759.86) |
-3.97% | Details | |
| 10/17/2023 | Nkarta Inc. | NKTX | Upgrade | Strong Buy (Outperform) |
1.48 (2.50) |
68.92% | Details | |
| 7/18/2023 | BridgeBio Pharma | BBIO | Maintain | Outperform (N/A) |
|
Details | ||
| 6/28/2023 | Nkarta Inc. | NKTX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/5/2023 | Galapagos NV | GLPG | Upgrade | Outperform (Market Perform) |
40.50 (32.92) |
-18.72% | Details | |
| 4/19/2023 | Relay Therapeutics | RLAY | Upgrade | Strong Buy (Outperform) |
11.62 (9.89) |
-14.89% | Details | |
| 4/13/2023 | Relay Therapeutics | RLAY | New Coverage | Outperform (N/A) |
18.02 (9.89) |
-45.12% | Details | |
| 3/23/2023 | Regeneron Pharma | REGN | Upgrade | Market Perform (Underperform) |
751.30 (759.86) |
1.14% | Details | |
| 3/13/2023 | Seagen | SGEN | Downgrade | Market Perform (Strong Buy) |
172.61 (228.74) |
32.52% | Details | |
| 3/6/2023 | BridgeBio Pharma | BBIO | Maintain | Outperform (N/A) |
|
Details | ||
| 2/17/2023 | Blueprint Medicines | BPMC | Maintain | Strong Buy (N/A) |
|
Details | ||
| 2/16/2023 | Seagen | SGEN | Upgrade | Strong Buy (Outperform) |
140.82 (228.74) |
62.43% | Details | |
| 11/9/2022 | Compass Therapeutics | CMPX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/8/2022 | Ocular Therapeutix | OCUL | Maintain | Strong Buy (N/A) |
|
Details | ||
| 11/7/2022 | Galapagos NV | GLPG | Maintain | Market Perform (Outperform) |
|
Details | ||
| 10/28/2022 | Seagen | SGEN | Maintain | Outperform (N/A) |
|
Details | ||
| 10/26/2022 | Regeneron Pharma | REGN | Downgrade | Underperform (Market Perform) |
737.15 (759.86) |
3.08% | Details | |
| 10/14/2022 | LianBio | LIAN | Maintain | Outperform (N/A) |
|
Details | ||
| 10/13/2022 | Xencor, Inc. | XNCR | Upgrade | Strong Buy (Outperform) |
26.52 (11.32) |
-57.32% | Details | |
| 9/19/2022 | bluebird bio | BLUE | Maintain | Outperform (N/A) |
|
Details | ||
| 8/26/2022 | Simulations Plus | SLP | Maintain | Outperform (N/A) |
|
Details | ||
| 8/10/2022 | Allogene | ALLO | Downgrade | Market Perform (Outperform) |
15.96 (2.30) |
-85.59% | Details | |
| 8/5/2022 | Cytokinetics | CYTK | Maintain | Outperform (N/A) |
|
Details | ||
| 8/2/2022 | Blueprint Medicines | BPMC | Maintain | Strong Buy (N/A) |
|
Details | ||
| 8/2/2022 | bluebird bio | BLUE | Upgrade | Outperform (Market Perform) |
4.05 (4.97) |
22.72% | Details | |
| 6/29/2022 | Seagen | SGEN | New Coverage | Outperform (N/A) |
178.47 (228.74) |
28.17% | Details | |
| 6/3/2022 | Bristol-Myers Squibb Co. | BMY | Downgrade | Market Perform (Outperform) |
75.07 (60.29) |
-19.69% | Details | |
| 5/5/2022 | Allogene | ALLO | Maintain | Outperform (N/A) |
|
Details | ||
| 4/26/2022 | G1 Therapeutics | GTHX | Maintain | Outperform (Outperform) |
|
Details | ||
| 4/25/2022 | Nkarta Inc. | NKTX | Maintain | Outperform (N/A) |
|
Details | ||
| 4/4/2022 | Curis | CRIS | Downgrade | Market Perform (Outperform) |
2.43 (0.99) |
-59.26% | Details | |
| 3/29/2022 | Ayala Pharmaceuticals | AYLA | Maintain | Outperform (N/A) |
|
Details | ||
| 3/14/2022 | BridgeBio Pharma | BBIO | Maintain | Outperform (Outperform) |
|
Details | ||
| 3/10/2022 | Nkarta Inc. | NKTX | New Coverage | Outperform (N/A) |
10.34 (2.50) |
-75.82% | Details | |
| 3/10/2022 | Nkarta Inc. | NKTX | New Coverage | Outperform (N/A) |
10.34 (10.34) |
0% | Details | |
| 2/14/2022 | Regenxbio Inc. | RGNX | Maintain | Strong Buy (Strong Buy) |
|
Details | ||
| 12/27/2021 | BridgeBio Pharma | BBIO | Maintain | Outperform (N/A) |
|
Details | ||
| 12/22/2021 | Compass Therapeutics | CMPX | New Coverage | Outperform (N/A) |
3.01 (2.60) |
-13.62% | Details | |
| 11/24/2021 | LianBio | LIAN | New Coverage | Outperform (N/A) |
14.57 (0.32) |
-97.8% | Details | |
| 11/18/2021 | Cytokinetics | CYTK | New Coverage | Outperform (N/A) |
39.24 (36.63) |
-6.65% | Details | |
| 11/16/2021 | Xilio Therapeutics Inc | XLO | New Coverage | Outperform (N/A) |
22.20 (0.53) |
-97.61% | Details | |
| 11/9/2021 | Blueprint Medicines | BPMC | Maintain | Strong Buy (N/A) |
|
Details | ||
| 10/15/2021 | Ocular Therapeutix | OCUL | Maintain | Strong Buy (N/A) |
|
Details | ||
| 10/13/2021 | Curis | CRIS | New Coverage | Outperform (N/A) |
7.54 (0.99) |
-86.87% | Details | |
| 10/7/2021 | Tarsus Pharmaceuticals | TARS | Maintain | Strong Buy (N/A) |
|
Details | ||
| 9/23/2021 | Allogene | ALLO | Upgrade | Outperform (Market Perform) |
25.67 (2.30) |
-91.04% | Details | |
| 8/24/2021 | Regeneron Pharma | REGN | Maintain | Market Perform (N/A) |
|
Details | ||
| 7/19/2021 | Cytokinetics | CYTK | Maintain | Outperform (N/A) |
|
Details | ||
| 6/29/2021 | Tarsus Pharmaceuticals | TARS | Maintain | Strong Buy (N/A) |
|
Details | ||
| 3/26/2021 | Cytokinetics | CYTK | Maintain | Outperform (N/A) |
|
Details | ||
| 2/24/2021 | Xencor, Inc. | XNCR | Upgrade | Outperform (Market Perform) |
48.35 (26.52) |
-45.15% | Details | |
| 2/19/2021 | Galapagos NV | GLPG | Upgrade | Outperform (Market Perform) |
83.80 (32.92) |
-60.72% | Details | |
| 2/16/2021 | G1 Therapeutics | GTHX | Maintain | Outperform (N/A) |
|
Details | ||
| 2/11/2021 | Regenxbio Inc. | RGNX | Maintain | Strong Buy (N/A) |
|
Details | ||
| 2/2/2021 | Sage Therapeutics | SAGE | New Coverage | Market Perform (N/A) |
80.65 (8.68) |
-89.24% | Details | |
| 1/6/2021 | Regenxbio Inc. | RGNX | Upgrade | Strong Buy (Outperform) |
44.91 (8.65) |
-80.74% | Details | |
| 11/30/2020 | Sage Therapeutics | SAGE | Downgrade | Market Perform (Outperform) |
75.57 (8.68) |
-88.51% | Details | |
| 11/17/2020 | G1 Therapeutics | GTHX | Downgrade | Outperform (Strong Buy) |
13.19 (7.15) |
-45.79% | Details | |
| 11/13/2020 | Ocular Therapeutix | OCUL | Maintain | Strong Buy (N/A) |
|
Details | ||
| 11/12/2020 | Adverum Biotechnologies | ADVM | Upgrade | Market Perform (Underperform) |
13.37 (4.36) |
-67.39% | Details | |
| 11/10/2020 | Tarsus Pharmaceuticals | TARS | New Coverage | Strong Buy (N/A) |
23.19 (73.26) |
215.91% | Details | |
| 10/26/2020 | Amgen | AMGN | Upgrade | Outperform (Market Perform) |
227.98 (369.53) |
62.09% | Details | |
| 10/16/2020 | Blueprint Medicines | BPMC | Maintain | Strong Buy (N/A) |
|
Details | ||
| 10/16/2020 | Simulations Plus | SLP | New Coverage | Outperform (N/A) |
71.90 (12.22) |
-83% | Details | |
| 10/8/2020 | Cytokinetics | CYTK | Downgrade | Outperform (Strong Buy) |
27.66 (60.41) |
118.4% | Details | |
| 10/8/2020 | Amgen | AMGN | Downgrade | Market Perform (Outperform) |
257.67 (369.53) |
43.41% | Details | |
| 9/22/2020 | Bristol-Myers Squibb Co. | BMY | Maintain | Outperform (N/A) |
|
Details | ||
| 9/21/2020 | Amgen | AMGN | Maintain | Outperform (N/A) |
|
Details | ||
| 8/10/2020 | Sage Therapeutics | SAGE | Upgrade | Outperform (Market Perform) |
50.70 (75.57) |
49.05% | Details | |
| 7/28/2020 | Bristol-Myers Squibb Co. | BMY | New Coverage | Outperform (N/A) |
57.85 (60.29) |
4.22% | Details | |
| 7/14/2020 | Blueprint Medicines | BPMC | Maintain | Strong Buy (N/A) |
|
Details | ||
| 7/10/2020 | Cytokinetics | CYTK | New Coverage | Strong Buy (N/A) |
26.92 (27.66) |
2.75% | Details | |
| 6/26/2020 | Adverum Biotechnologies | ADVM | Downgrade | Underperform (Market Perform) |
23.32 (13.37) |
-42.67% | Details | |
| 6/11/2020 | Magenta Therapeutics | MGTA | Maintain | Outperform (N/A) |
|
Details | ||
| 6/10/2020 | Ayala Pharmaceuticals | AYLA | New Coverage | Outperform (N/A) |
15.16 (0.50) |
-96.7% | Details | |
| 6/1/2020 | Allogene | ALLO | Downgrade | Market Perform (Outperform) |
46.54 (25.67) |
-44.84% | Details | |
| 4/28/2020 | Blueprint Medicines | BPMC | Maintain | Strong Buy (N/A) |
|
Details | ||
| 3/30/2020 | Amgen | AMGN | Upgrade | Outperform (Market Perform) |
198.49 (257.67) |
29.82% | Details | |
| 3/3/2020 | Ocular Therapeutix | OCUL | Upgrade | Strong Buy (Outperform) |
4.69 (10.27) |
118.98% | Details | |
| 2/20/2020 | bluebird bio | BLUE | Downgrade | Market Perform (Strong Buy) |
88.22 (4.97) |
-94.37% | Details | |
| 2/19/2020 | bluebird bio | BLUE | Downgrade | Market Perform (Strong Buy) |
88.22 (4.97) |
-94.37% | Details | |
| 2/10/2020 | Ocular Therapeutix | OCUL | Maintain | Outperform (N/A) |
|
Details | ||
| 1/6/2020 | BridgeBio Pharma | BBIO | Maintain | Outperform (N/A) |
|
Details | ||
| 12/24/2019 | Regeneron Pharma | REGN | New Coverage | Market Perform (N/A) |
375.62 (759.86) |
102.29% | Details | |
| 12/24/2019 | Amgen | AMGN | New Coverage | Market Perform (N/A) |
243.06 (198.49) |
-18.34% | Details | |
| 11/5/2019 | Blueprint Medicines | BPMC | Upgrade | Strong Buy (Outperform) |
67.12 (129.46) |
92.88% | Details | |
| 9/11/2019 | Blueprint Medicines | BPMC | Upgrade | Outperform (Market Perform) |
72.90 (67.12) |
-7.93% | Details | |
| 8/15/2019 | Blueprint Medicines | BPMC | New Coverage | Market Perform (N/A) |
85.76 (72.90) |
-15% | Details | |
| 8/7/2019 | Xencor, Inc. | XNCR | Downgrade | Market Perform (Outperform) |
46.27 (48.35) |
4.5% | Details | |
| 7/26/2019 | BridgeBio Pharma | BBIO | New Coverage | Outperform (N/A) |
28.12 (65.36) |
132.43% | Details | |
| 7/15/2019 | Galapagos NV | GLPG | Downgrade | Market Perform (Strong Buy) |
145.75 (83.80) |
-42.5% | Details | |
| 6/14/2019 | BioTime, Inc. | BTX | New Coverage | Market Perform (N/A) |
1.00 (6.42) |
542% | Details | |
| 6/14/2019 | Regenxbio Inc. | RGNX | New Coverage | Outperform (N/A) |
46.85 (8.65) |
-81.54% | Details | |
| 6/14/2019 | Adverum Biotechnologies | ADVM | New Coverage | Market Perform (N/A) |
11.06 (23.32) |
110.85% | Details | |
| 5/21/2019 | Ocular Therapeutix | OCUL | Downgrade | Outperform (Strong Buy) |
3.37 (4.69) |
39.17% | Details | |
| 3/15/2019 | Xencor, Inc. | XNCR | New Coverage | Outperform (N/A) |
29.28 (46.27) |
58.03% | Details | |
| 3/15/2019 | Magenta Therapeutics | MGTA | New Coverage | Outperform (N/A) |
14.27 (0.70) |
-95.09% | Details | |
| 3/15/2019 | Gritstone Oncology | GRTS | New Coverage | Outperform (N/A) |
10.74 (0.03) |
-99.72% | Details | |
| 3/14/2019 | Allogene | ALLO | New Coverage | Outperform (N/A) |
26.89 (46.54) |
73.08% | Details | |
| 3/8/2019 | Ocular Therapeutix | OCUL | Maintain | Strong Buy (N/A) |
|
Details | ||
| 1/7/2019 | Loxo Oncology | LOXO | Downgrade | Market Perform (Strong Buy) |
139.87 (234.80) |
67.87% | Details | |
| 12/3/2018 | Ocular Therapeutix | OCUL | Maintain | Strong Buy (N/A) |
|
Details | ||
| 11/15/2018 | Ocular Therapeutix | OCUL | New Coverage | Strong Buy (N/A) |
5.29 (3.37) |
-36.29% | Details | |
| 11/15/2018 | Loxo Oncology | LOXO | New Coverage | Strong Buy (N/A) |
159.08 (139.87) |
-12.08% | Details | |
| 11/15/2018 | Galapagos NV | GLPG | New Coverage | Strong Buy (N/A) |
102.79 (145.75) |
41.79% | Details |
